12 February 2026

Strong start to the new financial year for the Synektik Group

The WSE—listed provider of advanced medical technologies and manufacturer of radiopharmaceuticals continues to gain momentum. In the first quarter of the 2025 financial year (October–December 2025), the Synektik Group increased total revenues by 12% to PLN 228 million, while EBITDA from continuing operations rose by 18% to PLN 59.8 million. The Group's growth is being driven both by dynamically expanding recurring revenues in both segments and by higher sales of medical equipment.

Net profit from continuing operations (excluding the result of the Center for Research on New Molecules, planned to be spun off into Syn2bio) amounted to PLN 43.1 million in the first quarter of the current financial year, representing an 18% year-on-year increase. The business earmarked for separation closed the quarter with a net loss of PLN 8.1 million, related to R&D expenditures, including work carried out under the cardiac tracer project.

For yet another consecutive quarter, the segment covering sales of advanced medical devices and IT solutions recorded double-digit growth in both revenues and results. Sales of medical equipment, IT solutions and service contracts increased year on year by 12% to PLN 214.1 million (excluding intra-group transactions), while segment EBITDA rose by one fifth to PLN 60.6 million. The radiopharmaceuticals segment generated a 15% increase in sales in the past quarter to PLN 13.9 million (excluding intra-group transactions), with EBITDA rising year on year from PLN 3.9 million to PLN 4.1 million.

The Group's recurring revenues—generated from the supply of consumables and accessories, the provision of services, and the sale of radiopharmaceuticals under long-term customer contracts—rose by 32% year on year to PLN 101.1 million.

- The first quarter of the new 2025 financial year was both intensive and successful for the Synektik Group from a business perspective. Strong sales activity in the area of equipment and IT solutions resulted in a satisfactory level of new orders, some of which will be executed in subsequent quarters. Our success is the result of many years of consistent efforts to build a position as a leading provider of innovative solutions for medicine. We are intensively working to expand the Group's portfolio with further breakthrough technologies and to reach new customers with our offering. Under an agreement signed a few weeks ago with HistoSonics, the Synektik Group has become one of the first distributors in Europe of the Edison system—an innovative solution in the field of completely non-invasive and highly effective soft-tissue tumor ablation, known as histotripsy. As early as 2026, under a new agreement with Intuitive, we will expand our distribution of da Vinci robotic systems to Ukraine. We continue to highly value the Group's growth potential, based on its position as one of the leaders of the technological transformation of healthcare systems in Central Europe. Our goal—both short- and long-term—is to translate this potential into growth in the scale of the Group's operations - comments **Cezary Kozanecki, President and Founder of Synektik.**

In the first quarter of the 2025 financial year, the Group secured contracts for the supply of medical equipment worth PLN 148.0 million, 30% higher than the value of contracts signed in the corresponding period of 2024. Sales growth was supported by both the Company's broad product offering and favorable market conditions, related to the execution of tenders financed under the National Recovery and Resilience Plan (NRRP). The Group entered the second quarter of the financial year with an equipment supply backlog of PLN 73.2 million and open sales projects worth nearly PLN 166 million.

Dariusz Korecki, Vice President of Synektik, points out that the combined value of concluded but unexecuted contracts and open sales projects as of the end of December 2025 exceeded PLN 239 million and was 87% higher than at the end of 2024, which constitutes a very strong indicator for the Group's results in the coming quarters. - *A strong, diversified product portfolio, supported by many years of work on building market awareness of the therapeutic, diagnostic and economic advantages of the Group's solutions, underpins the scale of our engagement in the modernization of healthcare systems across the region* - adds Dariusz Korecki.

The new year for the Synektik Group and its stakeholders is not only marked by dynamic business growth. In February of this year, Synektik S.A. paid shareholders a record dividend of PLN 91.7 million, i.e. PLN 10.75 per share. The Group is also continuing its demerger process, under which R&D activities in the field of innovative radiopharmaceuticals, including the cardiac tracer project, will be separated into the listed company Syn2bio S.A. The Syn2bio prospectus, prepared in connection with a planned share issue addressed to Synektik S.A. shareholders, is currently under review by the Polish Financial Supervision Authority (UKNF), and a week ago the first of three formal notices regarding the planned demerger of Synektik S.A. was published. In the Management Board's assessment, the process of dividing the Group and listing Syn2bio will be completed in the second quarter of this year.

About the Synektik Group

The Synektik Group is a leading producer of advanced radiopharmaceuticals and medical IT solutions (including the Zbadani.pl platform and SynDose dose-monitoring app), a provider of specialist service and measurement support, and a distributor of innovative medical devices used in diagnostics and therapy across radiology, oncology, cardiology and neurology.

In medical-device distribution, the company works with a broad line-up of global manufacturers of diagnostic and therapeutic products and, on the strength of this portfolio and its expertise, delivers, among other things, hybrid operating theatres on a turnkey basis.

Synektik is the exclusive distributor in Poland, Czechia, Slovakia, Lithuania, Latvia and Estonia of da Vinci robotic systems for minimally invasive surgery and Symani robots for micro- and supermicrosurgery. The company is also the exclusive distributor in Poland, Czechia and Slovakia of non-invasive neurosurgery systems (using MRgFUS ultrasound technology for the treatment of essential tremor and Parkinson's disease-related tremor).

The group operates three radiopharmaceutical production facilities in Poland, one of which also serves as an R&D centre for new products in oncology, cardiology and neurology. The group is also developing its own clinical research centre and is a leading domestic supplier of specialized radiopharmaceuticals used, among other things, in diagnosing hepatocellular carcinoma and prostate cancer and its bone metastases. The group's flagship development project is the cardiac tracer—an innovative radiopharmaceutical with global potential in coronary artery disease diagnostics, currently in clinical trials.

In the most recent financial year (1 October 2024 – 30 September 2025), the Synektik Group generated sales revenue of nearly PLN 682 million (+9% y/y), achieved adjusted EBITDA of almost PLN 178 million (+24% y/y), and earned a net profit of close to PLN 103 million (+25% y/y).

For more information visit **www.synektik.pl**

Contact:

MakMedia Group
Błażej Dowgielski,
tel.: +48 692 823 744
e-mail: b.dowgielski@makmedia.pl